Uncertainties surrounding the U.S. pharmaceutical sector and the turbulent development in global stock markets have led to ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Access our live advanced streaming chart for Akero Therapeutics Inc stock, free of charge. This unique "area" or candle chart enables you to clearly notice the movements of this Akero Therapeutics ...

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO ), please contact Fletcher Moore by email at ... or (212) 709-8245. You may be able to seek monetary damages, corporate governance ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across ...

Piotr Swat / SOPA Images / LightRocket via Getty Images Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a patient taking it died.

Akero Therapeutics Inc. (NASDAQ: AKRO) is a clinical-stage biopharmaceutical company also based near San Francisco. Shares soared earlier in the year on news of positive trial results for a liver ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...